2006 U.S. Market – Advanced Drug Delivery Systems:

Probing the Route to Growth

New Developments, New Technologies, Companies, and Trends

Published by Fuji-Keizai and MRG, Inc.
October 2005, 166 pages

Hard Copy Print Edition $1,295.00 USD
PDF Single-Departmental License $1,945.00 USD
PDF Corporate-Wide License $2,590.00 USD
*Available in English or Japanese

Executive Overview

Drug delivery systems have grown to become important technology platforms used by companies in the pharmaceutical, biotechnology and medical device industries in recent years. Drug delivery technology is a resource used by companies to survive in the market. Some companies use it has an enabler of new opportunities in an expanding market. This report takes a broad look at the drug delivery system market, the many technologies, the companies, and the dynamics of this interesting business.

This study is an update to Fuji-Keizai’s strong selling report about drug delivery and provides the reader with new technology and business information. The report provides readers with information and analysis about key developments driving the industry in the middle of 2005. People know about drug delivery systems through seeing daily TV commercials promoting the benefits of a new contraceptive patch, the new dry powder inhaler that helps people with allergies breath easier, or the new once a month pill to help with osteoporosis. These TV ads tell us about the benefits of using drug delivery systems.

This report estimates that the US drug delivery market will reach nearly $91 billion by 2009. The US drug delivery industry is prospering and is transforming ordinary drugs into better drugs optimized for a broad range of applications. Drug delivery is helping to expand other pharmaceutical industry sectors such as biotechnology drugs, generic drugs, specialty pharmaceuticals and more. Major pharmaceutical firms use the technology to extend their drug product life cycles.

Drug delivery will help drug companies respond to nearly $80 billion in lost value for drugs with expiring patents during the next few years. More than 21 figures and tables illustrate this report. Detailed information about the activities of twenty-seven companies important to the expanding drug delivery market is profiled. Readers working in healthcare industries including executives, managers, investors, entrepreneurs, consultants and others may find this report of interest.

---

Table of Contents

1. The Drug Delivery System Market and Business
1.1 Key Findings
1.2 Current and Future DDS Market and Business Potential
1.2.1 More Growth Expected in Next Few Years
1.2.2 The Pharmaceutical Industry is Facing a Productivity Gap
1.2.3 Profitable Drugs To Lose Patent Protection and Market Exclusivity
1.2.4 Using Patent Extension Strategies for Product Life-Cycle Management
1.3 Partnership Strategy
1.3.1 New Drugs Continue to Hit the Market in Near Term
1.3.2 Big Pharmas Cannot Work Alone to Make Drugs
1.4 Technology Exposure
1.4.1 Commercial Interests
1.4.2 Post-Genomic Advances
1.4.3 Emerging Targeted Therapies
1.4.4 Large Molecule Biopharmaceuticals: Protein and Peptide Drugs
1.4.5 More Knowledge About Disease Mechanisms
1.5 Drivers and Resistors to DDS Reformulation
1.5.1 Market is Fragmented
1.5.2 The Field Continues To Expand
1.6 Strategic Analysis of key DDS Players
1.6.1 Drug Delivery Technologies Preferred by the Pharma Industry
1.6.2 Drug Delivery Business Models Continue Shift to Products
2.10.2.4 Modified Blood Cells
2.10.2.5 Nanoparticles     
2.10.2.6 Viral Assisted Intracellular Gene Delivery
2.10.2.7 Non-Viral Intracellular Gene Delivery

2. Key Drug Delivery Technology & Reformulation and Roadmap
2.1 Key Technology Findings
2.2 Oral Drug Delivery
2.3 Bone Marrow Infusion
2.3.2 Delivery of Drugs into Bone Marrow
2.3.3 Delivery of Bone Marrow-based Stem Cell
2.3.4 Delivery of Other Cell Therapies to Bone Marrow
2.4 Injectable Drug Delivery (Parenteral)
2.5 Transdermal Drug Delivery
2.6 Transmucosal Drug Delivery
2.7 Organ System Specific Drug Delivery
2.7.1 Genito-Urinary Tract (GU)
2.7.2 Nasal Delivery to Central Nervous System (CNS)
2.7.3 Cardiovascular System (CV)
2.7.4 Ocular Drug Delivery
2.7.5 Pulmonary Drug Delivery
2.7.6 Stomach & Gastrointestinal Tract (GI)
2.8 Controlled Release Systems
2.9 Novel Packaging and Formulations
2.9.1 Orally Disintegrating Tablets (Fast Dissolving)
2.9.2 Chewable Tablets
2.9.3 Solubility and Bioavailability Enhancement
2.10 Highly Targeted Drug Delivery
2.10.1 Polymer and Collagen Systems
2.10.2 Particle-Based Systems
2.10.2.1 Therapeutic Monoclonal Antibodies
2.10.2.2 Liposomes
2.10.2.3 Microparticles

3. Strategic Alliances and M&As
3.1 Traditional Drug Delivery Licensing Business Model
3.2 Drug Product Based Drug Delivery Business Model
3.3 Driving the Need to Partner
3.4 Alliance Analysis, 2003 to Mid-2005

4. Emerging Technology for Drug Delivery
4.1 Analysis of Emerging Drug Delivery Technologies
4.2 Nano Drug Delivery
4.3 Protein Drug Delivery
4.4 Polymer Development
4.5 Therapeutic Monoclonal Antibody Development
4.6 PEGnology Development
4.7 Inhalation System Development
4.8 Buccal Delivery Development
4.9 Ocular Delivery Development
4.10 Vaccine Delivery Development
4.11 Other Emerging Technology

5. Market Forecast and Future Outlook
5.1 US Drug Delivery Market Trends
5.1.1 A Strong Market
5.1.2 Solutions for Unmet Medical Needs
5.1.3 Doctors and Patients Prefer No Pain
5.1.4 Drug Delivery Helps Pharmaceutical Firms to Compete
5.2 US Drug Delivery Mkt Size by Segment 2004-2009
5.2.1 Market Segments
5.2.2 Oral Drug Delivery
5.2.3 Parenteral Drug Delivery
5.2.4 Injection Devices
5.2.5 Inhaled Drug Delivery      
5.2.6 Inhaler Devices (Nebulizer, Spacers)
5.2.7 Transdermal Drug Delivery
5.2.8 Implant Drug Delivery
5.2.9 Transmucosal Drug Delivery
5.2.10 Therapeutic Antibodies
5.2.11 Therapeutic & Cancer Vaccines           
5.2.12 Gene Therapy/Delivery
5.2.13 Other Drug Delivery
5.3 Market Shares of the US Drug Delivery Market, 2004 and 2009
5.4 Platforms/ Products in the Competitive Vendor Landscape

6. Selected Legal Disputes
6.1 IVAX, Teva Pharmaceutical Industries Ltd., et al v. Eli Lilly
6.2 Johnson & Johnson v. Boston Scientific
6.3 Chiron Corporation v. Corus Pharma
6.4 Novartis Pharmaceuticals Corp., et al v. Sun Pharmaceutical Industries Ltd.     
6.5 GlaxoSmithKline Plc v. Par Pharmaceutical Companies
6.6 Santarus, Inc. v. TAP Pharmaceutical Products
6.7 Travanti Pharma Inc. v. IOMED

7. Activities of Leading Drug Delivery Firms
Common Research Items - Company Profile
• Contact
• Established Year
• Revenue
• # of Employees
• Company Overview, Technology & Products
• Alliances, Mergers and Acquisitions Other Findings

7.1 DNA/RNA Delivery (4)
7.2 Multiple Delivery Platform (4)
7.3 Nasal/Lung Delivery (3)
7.4 Other Drug Delivery (3)
7.5 Particle Drug Delivery (3)        
7.6 Speciality Pharma (2)
7.7 Therapeutic MAb Delivery (2)
7.8 Transdermal/Transmucosal Delivery (4)

8. The Top 50 Drug Delivery Companies

9. Appendix A: Links to Drug Delivery Websites
9.1 Pharmaceutical and Biotechnology Industry Sites
9.2 Government Regulatory Agencies
9.3 Pharmaceutical Industry News Sites

10. Appendix B: Glossary of Drug Delivery Terms

List of Tables
T-1 US Drug Delivery Systems Mkt Size, 2004-2009
T-2 Analysis of Alliances, Mergers and Acquisitions of DDS Companies
T-3 Selected Drug Delivery Company Alliances in 2005 (First Half)
T-4 Selected Drug Delivery Company Alliances in 2004
T-5 Selected Drug Delivery Company Alliances in 2003
T-6 Emerging Drug Delivery Technologies
T-7 US Drug Delivery Market Size, Revenues by Segments, 2004-2009
T-8 US DDS MKt Revenues by Share, 2004 and 2009
T-9 Leading Drug Delivery Companies Mapped by Competing Platforms/Products
T-10 Legal Disputes Among Selected Companies Involving Drug Delivery
T-11 The Top 50 WW Drug Delivery Companies by Total Revenues (2004 $M)

List of Illustrations
Fig 1 - US Drug Delivery Systems Mkt Size  2004-2009
Fig 2 - The GI Tract & Oral Drug Delivery Route (by Mouth)
Fig 3 - Intraosseous (Bone Marrow) Infusion
Fig 4 - Injection Based Drug Delivery Methods            
Fig 5 - Transdermal Patch Drug Delivery
Fig 6 - 3M's Multi-layer Drug-in-Adhesive Transdermal Patch
Fig 7 - Johnson & Johnson's Drug-Coated Stent
Fig 8 - Pulmonary Delivery Solutions
Fig 9 - Penwest's TIMERx(r) Drug Delivery Technology
Fig 10 - US Drug Delivery Market Size, Revenues by Segment, 2004-2009
Fig 11 - US DDS Mkt Revenues by Share, 2004 & 2009

2006 U.S. Market – Advanced Drug Delivery Systems: Probing the Route to Growth: New Developments, New Technologies, Companies, and Trends — October 2005 is 166 pages and is available in English or Japanese languages. Hard Copy edition for $1,295.00 US, a PDF single-departmental license for $1,945.00 US, and a PDF Corporate-Wide License for $2,590.00 US. For more information or to order the report, contact Rob Smith at 408-524-9767 or rsmith@mrgco.com.

Order Form